{"id":34660,"date":"2026-03-07T03:27:09","date_gmt":"2026-03-07T03:27:09","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/34660\/"},"modified":"2026-03-07T03:27:09","modified_gmt":"2026-03-07T03:27:09","slug":"novo-nordisk-and-hims-hers-end-bitter-legal-feud-with-surprise-weight-loss-drug-deal-report-hims-hers-health-nysehims-eli-lilly-nyselly","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/34660\/","title":{"rendered":"Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report – Hims & Hers Health (NYSE:HIMS), Eli Lilly (NYSE:LLY)"},"content":{"rendered":"

Novo Nordisk AS (NYSE:<\/a>NVO<\/a>) and Hims & Hers Health Inc. (NYSE:<\/a>HIMS<\/a>) have reportedly ended their public feud<\/a>, with the drugmaker deciding to sell its weight-loss drug on the telehealth platform.<\/p>\n

The announcement regarding the new partnership is expected as soon as Monday, Bloomberg reported<\/a> on Friday, citing a person familiar with the matter.<\/p>\n

Last month, Novo Nordisk sued Hims & Hers after the latter began marketing a compounded version of its new weight-loss pill. The company alleged patent violations, citing the ingredient used in Wegovy.<\/p>\n

In 2025, Novo Nordisk and Hims & Hers also announced a partnership, but the drugmaker ended the agreement abruptly after the platform declined to stop promoting the compounded versions of the drugs<\/a>.<\/p>\n

\u201cWe are always in conversation with companies that can help improve patient access to FDA-approved medicines for people living with chronic diseases. These talks happen on an ongoing basis, and we will discuss if\/when we have final details to share,\u201d a Novo Nordisk spokesperson told Benzinga in an emailed statement.<\/p>\n

Hims & Hers did not immediately respond to Benzinga<\/a>‘s request for comment.<\/p>\n

Weight-Loss Drug Market Pressure Builds<\/p>\n

The competition has grown due to the recent supply shortages. However, the U.S. Food and Drug Administration has indicated plans to increase scrutiny of copycat weight-loss drugs.<\/p>\n

Price Action: After-hours trading saw shares of Hims & Hers Health surge 39.77% to $22, after closing Friday down 0.88% at $15.74. Shares of Novo Nordisk closed at $38.58 on Friday, down 1.25%, but rose 2.12% to $39.40 in after-hours trading, according to Benzinga Pro.<\/p>\n

Benzinga’s Edge Stock Rankings show that Novo Nordisk is exhibiting weakness<\/a> across the short, medium, and long-term, although its Quality score ranks in the 76th percentile.<\/p>\n

Image via Shutterstock<\/p>\n

Market News and Data brought to you by Benzinga APIs<\/a><\/p>\n

\u00a9 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.<\/p>\n

To add Benzinga News as your preferred source on Google, click here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk AS (NYSE:NVO) and Hims & Hers Health Inc. (NYSE:HIMS) have reportedly ended their public feud, with…\n","protected":false},"author":2,"featured_media":34661,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[20193,2089,2090,2088,2084,272,352,2095,8257,2096,16231],"class_list":{"0":"post-34660","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-category-contracts","9":"tag-category-health-care","10":"tag-category-legal","11":"tag-category-news","12":"tag-cms-wordpress","13":"tag-novo-nordisk","14":"tag-pageisbzpro-bz","15":"tag-symbol-hims","16":"tag-symbol-lly","17":"tag-symbol-nvo","18":"tag-tag-weight-loss-drug"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116185769137322282","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/34660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=34660"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/34660\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/34661"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=34660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=34660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=34660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}